Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities
December 21, 2020 08:00 ET
|
Aileron Therapeutics, Inc.
Aileron’s 2021 strategic priorities aim to advance its vision to bring chemoprotection to all patients with p53-mutant cancers regardless of cancer indication or chemotherapy. Key anticipated...
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
November 12, 2020 19:03 ET
|
Aileron Therapeutics, Inc.
Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation...
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
October 24, 2020 04:35 ET
|
Aileron Therapeutics, Inc.
First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers from chemotherapy-induced toxicities and side...
Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
October 20, 2020 09:24 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b...
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
October 12, 2020 07:00 ET
|
Aileron Therapeutics, Inc.
Aileron aims to create new paradigm of proactive prevention of chemotherapy-induced side effects to address significant unmet need among cancer patientsALRN-6924 is first and only chemoprotective...
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
September 21, 2020 18:07 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up...
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
September 10, 2020 08:45 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate...
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 05, 2020 16:10 ET
|
Aileron Therapeutics, Inc.
Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects-- Positive interim dose optimization data from...
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
August 03, 2020 08:10 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two...
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
August 03, 2020 08:00 ET
|
Aileron Therapeutics, Inc.
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecanPreviously reported...